HIMS 10-Q filed 2026-11-09 | Key takeaways
HIMS filed its 10-Q; the most relevant disclosure change is expanded Business combinations: Completed Eucalyptus acquisition in June 2026 for preliminary purchase price of $968.5M (cash of $225M, deferred payments of $683.9M, earn-out up to $96.6M); acquired YourBio Health in January 2026 for $153.0M (cash of $142.4M, earn-out of $10.6M); goodwill in.
Key takeaways
International revenue surged to $233.3M in Q3 2026 (26% of total) from $55.5M in Q3 2025, driven by Eucalyptus acquisition
Restructuring charges of $41.9M recorded YTD related to strategic shift in U.S. weight loss offering to focus on branded GLP-1 and limited compounded GLP-1
FTC and state regulators filed complaint in July 2026 alleging violations of FTC Act and ROSCA regarding subscription practices; $60M legal contingency accrual recorded
Receivables Purchase Agreement with JPMorgan Chase established for up to $400M; $434.5M in receivables sold YTD for net proceeds of $433.3M
2032 Convertible Notes issued for $402.5M in May 2026; combined with 2030 Convertible Notes, total net carrying value of $1.37B
Eucalyptus acquisition closed June 2026 for $968.5M (preliminary) with earn-out potential up to $96.6M; contributed approximately 15% of Q3 revenue
Key metrics
Disclosure changes
- Business combinations
Completed Eucalyptus acquisition in June 2026 for preliminary purchase price of $968.5M (cash of $225M, deferred payments of $683.9M, earn-out up to $96.6M); acquired YourBio Health in January 2026 for $153.0M (cash of $142.4M, earn-out of $10.6M); goodwill increased from $278.3M to $1.11B
Significant acquisition activity has materially changed the company's scale, international footprint, and cost structure - Legal proceedings
FTC and state regulators (Utah, California) filed complaint in July 2026 alleging violations of FTC Act and ROSCA regarding privacy, advertising, subscription, and cancellation practices; $60M legal contingency accrual recorded; motion to dismiss filed October 2026; putative class action filed based on same underlying facts
Material legal contingency with potential for permanent injunction, monetary relief, civil penalties, and business operational changes - Restructuring charges
In March 2026, announced strategic shift for U.S. weight loss offering to match global approach; recorded $3.8M in Q3 2026 and $41.9M YTD in restructuring and other related charges ($28.5M in cost of revenue, $13.4M in operating expenses)
Strategic pivot in weight loss business may impact future revenue trajectory and profitability - Receivables and receivables purchase facility
Receivables, net increased to $427.8M from $32.1M; includes manufacturer's discount and rebate receivables of $345.3M and loss recovery receivables of $26.0M; RPA with JPMorgan Chase provides up to $400M facility; sold $434.5M receivables YTD for net proceeds of $433.3M
Significant growth in receivables reflects new vendor rebate arrangements and receivables securitization provides liquidity - Revenue disaggregation
International revenue grew to $233.3M (26% of total) in Q3 2026 from $55.5M in Q3 2025; U.S. revenue grew to $657.1M from $543.5M
International operations now represent significant portion of revenue following Eucalyptus acquisition - Convertible notes
2032 Convertible Notes of $402.5M issued May 2026 (net proceeds $389.5M, conversion price $29.53, convertible into 33.8590 shares per $1,000); combined net carrying value of $1.37B for both note series
Additional debt financing increases leverage and future dilution risk
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow HIMS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.